A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
NCT02925104
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
cMET Dysegulation Advanced Solid Tumors
Interventions
DRUG:
INC280
Sponsor
Novartis Pharmaceuticals